Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Relypsa, Inc.
Rajiv Agarwal; Patrick Rossignol; Alain Romero; Dahlia Garza; Martha R Mayo; Suzette Warren; Jia Ma; William B White; Bryan Williams
Biometrics, Relypsa, a Vifor Pharma Group Company, Redwood City, CA, USA.